Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-CAR032 in Metastatic Castration-Resistant Prostate Cancer
NCT07344311Phase 1Recruiting
- Sponsor
- AbelZeta
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A-CAR032 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AbelZeta. Primary endpoint: Safety at 15 years. Started Jan 2026; status: recruiting.
02
Drugs
A-CAR032
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07344311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344311.